BXP vs ZYME · rev $3.48B vs rev $76.3M
Boston Properties Inc (BXP) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Boston Properties Inc (BXP) is a reit - office company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported BXP revenue for 2025-12-31 was $3.48B. Net income was $276.8M. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BXP currently screens at market cap $12.12B.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
BXP currently screens at market cap $12.12B. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the BXP and ZYME stock pages for the full models.
Not investment advice.